EXPERT CONSENSUS ON PATIENT-REPORTED OUTCOMES FOR THE **PCN470** MANAGEMENT OF PANCREATIC CANCER

Authors: Rivera F¹, Antía F², Macarulla T³, Mangues MA⁴, Muñoz A⁵, Comellas M⁶

Affiliations: ¹ Medical Oncology Service, Hospital Marqués de Valdecilla, Santander, Spain. ² Clinical Trails Unit, Hospital Universitario Marqués de Valdecilla, Santander, Spain³ Gastrointestinal Tumors Unit, Hospital Universitario Vall d' Hebrón, Barcelona, Spain. ⁴ Hospital Pharmacy Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. ⁵ Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain.⁶ Outcomes'10, Castellón, Spain.

INTRODUCTION

Systematic collection of patient-reported outcomes (PROs) is of increasing importance in cancer care since it improves symptom control¹ and patient-physician communication². Given the poor prognosis of pancreatic cancer, accurate monitoring of symptoms becomes critical to improve patient outcomes, health status and care.

Figure 3. Agreed PROs selected to be systematically collected

Fever	525 G	Do you have a fever (over 38°C)?	OYES ONO
		Have you been receiving chemotherapy in the last three weeks?	OYES ONO
Gastro-integ /bleeding	stinal	Have you had vomiting with bright red blood or a blackish appearence ("coffee grounds type")?	OYES ONO
		Have you had black, doughy, foul-smelling stools?	OYES ONO
Pain			

OBJECTIVE

This project aims to reach consensus on the most significant PROs in pancreatic cancer, from both patients and healthcare professionals'

perspectives, to be collected in clinical practice.

METHODS


Scientific Committee

The project was led by a Scientific Committee composed by 5 experts on pancreatic cancer management (n=3 oncologists, n=1 hospital pharmacist, n=1 nurse).

Phases of the project


Phases of the project are shown in Figure 1.

Figure 1. Phases of the project.





Two nominal groups structured with experts interviews (n=10 oncologists, n=4 hospital pharma-



Six semi-

with

patients

Second Scientific Committee meeting

0 = no pain; 10 = worst posible pain

na	Is the swelling asymmetrical? (Appears only in one side of the body)	OYES ONO
	Was the onset of swelling abrupt?	OYES ONO
	Is the swelling associated with redness of the skin or warmth?	OYES ONO
	In the past week, did you experience any swelling in any part of your body?	OYES ONO

10

Weight/ Apetite	0	I haven't lost weight or appetite	0
	1	I haven't lost some weight or appetite	0
	2	I've lost quite a lot of weight or my appetite	0
	3	I've lost a lot of weight or appetite	0
	4	I've lost significant amounts o weight or appetite	0


oiarrhea/ onstipation	What is the maximum number of loose or liquid stools you have had during the last week?	
Ę	Have you been more than 3 days without a bowel movement?	OYES ONO


lausea and	Have you had nausea?	O YES O	NO
omiting	Have nausea changed your eating habits?	O YES O	NO
(* * *)	Have you vomiting more than 3 times or more in 24 hours?	O YES O	NO
	Have you been vomiting for more than 3 days?	O YES O	NO

Asthenia/

Сс

Eden






- Initially, a literature review was performed to identify PROs in pancreatic cancer.
- Based on the results of the literature review and their clinical expertise, the **Scientific Committee** elaborated a list of PROs that was subsequently presented to healthcare professionals and patients.
- Two nominal groups with healthcare professionals (n=10 oncologists, n=4 hospital pharmacists, n=2 nurses) and 6 semi-structured inter**views** with patients were conducted to establish the most valuable PROs (consensus \geq 75% participants agree).
- Finally, the Scientific Committee determined the inclusion or did not of those PROs that not achieve consensus among nominal groups and semi-structured interviews (Figure 1).

RESULTS

A total of 49 disease-related signs and symptoms and/or its treatment that could be self-reported by the patient were identified during the Literature review (n=45) and by the Scientific Commitee (n=4). During nominal groups and semi-structured interviews 16 PROs were identified as the most significant. Of them, 6 reached consensus in both nominal groups and 9 were also considered valuable by patients. Finally, the Scientific Committee selected 14 PROs (Figure 2 and Figure 3).

0=no asthenia/fatigue 10=worst possible asthenia/fatigue

Dyspnea	0	I haven't had difficulty breathing	0
	1	I've had difficulty breathing with little efforts	0
	2	I have had difficulty breathing with moderate efforts	0
\frown	3	I have had difficulty breathing with small efforts	0
	4	I have had shortness of breath that has been disabling	0
	Has the	e shortness of breath or choking sensation appeared suddenly? O YES $oldsymbol{0}$	NO




0=no anxiety/depression/insomnia 10=worst possible no anxiety/depression/insomnia

Neuropathy	0	I have not had loss of sensation or strenght
	1	I have had a slight loss os sensation or strenght, which has not interested with my daily life
	2	I have had a loss of sensation or strenght that has meant extra efforts to perform my daily activities
	3	I have had a loss of sensation or strenght that causes thigns to fall off my hands
	4	I have had loss of sensation or strength that has been disabling



In the last week, have you experienced a progresive increase in abdominal perimeter?	OYES ONO
Has the increment of abdominal perimeter	OYES ONO

Figure 2. Identification and selection of most relevant PROs.



LR: Literature Review; SC: Scientific Committe; PROs: Patient Reported Outcomes



caused you significant pain or discomfort?

Change in the color of urine/stools and /or skin/eyes	In the past week, have you experienced a change in the color of your stool (light) or urine (dark) for more than 2 days?	OYES ONO
	Your skin or your eyes are yellow?	OYES ONO
Swallowing problems	Have you had mouth sores or discomfort from swallowing?	O YES O NO

CONCLUSIONS

The findings of the present project are the first step to implement the systematic collection of PROs that may enhance patient care and patient-physician communication in clinical practice.

REFERENCES

1. Basch et al. 2016. J Clin Oncol 34:557-565. 2. Yang et al. 2018 Support Care Cancer. 26(1):41-60.

$OUTC OMES^{10}$

ISPOR Europe 2019 / 2-6 November 2019, Copenhagen, Denmark